Chembio Diagnostics Inc  

(Public, NASDAQ:CEMI)   Watch this stock  
Find more results for CEMI
8.52
+0.16 (1.91%)
May 27 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 8.14 - 8.52
52 week 3.33 - 9.40
Open 8.28
Vol / Avg. 45,552.00/54,894.00
Mkt cap 83.80M
P/E     -
Div/yield     -
EPS -0.21
Shares 9.65M
Beta 1.03
Inst. own 16%
Aug 4, 2016
Q2 2016 Chembio Diagnostics Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
May 12, 2016
Q1 2016 Chembio Diagnostics Inc Earnings Call - Webcast
May 12, 2016
Q1 2016 Chembio Diagnostics Inc Earnings Release
Mar 8, 2016
Q4 2015 Chembio Diagnostics Inc Earnings Call
Mar 8, 2016
Q4 2015 Chembio Diagnostics Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -4.60% -9.88%
Operating margin -7.09% -14.65%
EBITD margin - -8.99%
Return on average assets -5.94% -10.46%
Return on average equity -6.94% -12.82%
Employees 155 -
CDP Score - -

Address

3661 Horseblock Rd
MEDFORD, NY 11763-2215
United States - Map
+1-631-9241135 (Phone)
+1-775-8849383 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Chembio Diagnostics, Inc. (Chembio), and its subsidiary, Chembio Diagnostic Systems, Inc., develop, manufacture, market and license rapid point-of-care diagnostic tests (POCTs) that detect infectious diseases. The Company's products available are rapid tests for the detection of human immunodeficiency virus (HIV) 1/2 antibodies, and a multiplex rapid test for the detection of HIV and Syphilis antibodies. The HIV 1/2 rapid tests employ in-licensed and lateral flow technologies that are used with all blood matrices as samples, and are manufactured in a standard cassette format, a dipstick format and a barrel format. Its HIV 1/2 rapid antibody detection test incorporates the Dual Path Platform (DPP) POCT technology. The DPP HIV 1/2 Assay detects antibodies to HIV 1 and 2 in oral fluid samples, as well as in all blood matrices. The Company's product pipeline includes a multiplex rapid test for earlier detection of HIV and a multiplex test that detects HIV and Syphilis specific antibodies.

Officers and directors

John J. Sperzel III President, Chief Executive Officer, Director
Age: 51
Bio & Compensation  - Reuters
Richard J. Larkin Chief Financial Officer
Age: 58
Bio & Compensation  - Reuters
Sharon Klugewicz Chief Operating Officer
Age: 47
Bio & Compensation  - Reuters
Javan Esfandiari Chief Science and Technology Officer
Age: 48
Bio & Compensation  - Reuters
Tom Ippolito Vice President - Regulatory Affairs, Quality Assurance and Quality Control
Age: 52
Bio & Compensation  - Reuters
Paul Lambotte Ph.D. Vice President - Product Development
Age: 63
Bio & Compensation  - Reuters
Michael K. Steele Vice President - Business Development, Sales and Marketing
Age: 48
Bio & Compensation  - Reuters
Katherine L. Davis Non-Executive Independent Chairman of the Board
Age: 58
Bio & Compensation  - Reuters
Barbara A. DeBuono M.D. Independent Director
Age: 60
Bio & Compensation  - Reuters
Peter T. Kissinger Ph.D. Independent Director
Age: 70
Bio & Compensation  - Reuters